Align Technology Inc Stock Price, News & Analysis

Align Technology (NASDAQ: ALGN), a global leader in digital orthodontics and restorative dentistry, has scheduled its second quarter 2025 financial results announcement for July 30, 2025, after market close at 4:00 p.m. ET.

The company will host a conference call at 4:30 p.m. ET to discuss the results, which will be accessible via webcast through the company's Investor Relations website. An archived version of the webcast will remain available for one month following the call.

Align Technology is known for its Invisalign® System, iTero™ intraoral scanners, and exocad™ CAD/CAM software. The company has served over 20.1 million patients through its network of 281.4 thousand doctor customers worldwide.

[]

Align Technology (NASDAQ:ALGN) hosted its 2025 Invisalign® Asia Pacific Summit in Bangkok, Thailand, attracting over 2,000 doctors and practice staff. The event celebrated reaching 20 million Invisalign smiles globally and 3 million smiles across Asia Pacific.

The three-day summit featured 60+ expert speakers and 50+ breakout sessions focusing on kids and teens, complex treatments, comprehensive dentistry, and practice growth. The Innovation Hub showcased developments including Invisalign First™, Invisalign® Palatal Expander System, and iTero Lumina™ Pro dental imaging system.

Additionally, the adjacent Align APAC University Forum at Chulalongkorn University gathered 300 delegates from 78 universities to discuss academic excellence and clinical training integration.

Align Technology (NASDAQ: ALGN) has launched integrated global marketing campaigns targeting kids and teens for its Invisalign clear aligner system. The initiative includes the 'Invisalign for Kids' consumer campaign educating parents about treatment benefits and the 'Growing Patients' professional campaign supporting doctors with product information. The campaigns highlight Align's extensive portfolio for growing patients, including the Invisalign Palatal Expander System, Invisalign First, and Invisalign System with mandibular advancement. This launch is part of Align's celebration of reaching 20 million Invisalign patients globally, with 5.8 million being kids and teens. The company emphasizes that children should be screened by orthodontists by age 7, offering Phase 1 treatment for ages 6-10 and Phase 2 treatment once permanent teeth are in place.

Align Technology (NASDAQ: ALGN) has awarded twelve research grants to universities globally through its fifteenth Annual Research Award Program, totaling $300,000 in funding. The grants support research across the Americas, Europe, and Asia Pacific regions, focusing on advancing orthodontic and dental research. The funded studies cover various topics related to Invisalign clear aligners, including adolescent treatment adherence, clinical consultation methods, attachment bonding precision, and comparative analyses with traditional orthodontic approaches. The research program received its highest number of applications since its inception 15 years ago. Applications underwent blind evaluation by an independent academic committee before final selection by Align Technology. The company aims to advance dental science and improve global dental care through these research initiatives.

Align Technology (NASDAQ: ALGN) has launched a new professional marketing initiative celebrating doctors' role in digital orthodontics, coinciding with their milestone of 20 million Invisalign smiles. The campaign, launching across EMEA and North America, features real stories from orthodontists who use Align's digital tools and technology.

Two main campaigns are being introduced: "We See Your Brilliance" launching digitally across EMEA in 7 languages on May 23rd at the European Aligner Society Congress 2025, and "The Innovators Behind the Smile" launching in North America on May 22nd. The initiative showcases authentic doctor stories through short-form videos across multiple media platforms, initially focusing on orthodontists, with plans to later include General Practitioner dentists.

Align Technology (NASDAQ: ALGN) has received NMPA approval in China for its Invisalign® Palatal Expander System, marking a significant expansion in the Asia Pacific region. The system, which will be commercially available in H2 2025, is designed for skeletal and dental expansion in patients with primary, mixed, and permanent dentition. This innovative direct 3D printed device offers a removable alternative to traditional palatal expanders. Combined with Invisalign First™ aligners, it provides doctors a complete early intervention solution for Phase 1 treatment, typically targeting patients aged 6-10. The system creates customized devices based on iTero™ intraoral digital scans and Align's proprietary orthodontic software. This approval is particularly significant as Phase 1 treatment represents 20% of orthodontic case starts annually and is growing.

Align Technology (NASDAQ: ALGN) has announced a new $1 billion stock repurchase program spanning the next three years. This program follows the completion of their previous $1 billion authorization from January 2023, which concluded on May 1, 2025. The company's CFO, John Morici, emphasized that this initiative reflects their strong balance sheet, robust cash flow generation, and confidence in capitalizing on market opportunities.

As of March 31, 2025, Align had approximately 73.1 million shares outstanding and $873.0 million in cash and cash equivalents. The company, known for its Invisalign® System, iTero™ intraoral scanners, and exocad™ CAD/CAM software, aims to balance capital return to shareholders while investing in strategic growth drivers.

Align Technology (NASDAQ: ALGN), a global leader in dental technology, has announced its participation in three upcoming financial conferences in May and June 2025. The company will present at the Bank of America Healthcare Conference in Las Vegas (May 13), the Stifel Jaws & Paws Conference in New York (May 28), and the Jefferies Global Healthcare Conference in New York (June 4).

Key executives including CEO Joe Hogan, CFO John Morici, and regional managing directors will represent the company. All presentations will be accessible via webcast through Align's Investor Relations website, with recordings available for approximately one month afterward.

Align Technology reported Q1 2025 financial results, marking its 20 millionth Invisalign patient milestone. The company's Q1 revenues reached $979.3 million, showing a slight decline of 1.8% year-over-year, impacted by foreign exchange headwinds of $31.1 million.

Clear Aligner volume grew 6.2% year-over-year to 642,305 cases, with teen patient segment increasing 13.3%. Clear Aligner revenues were $796.8 million, while Imaging Systems and CAD/CAM Services generated $182.4 million. Operating income stood at $131.1 million with a 13.4% margin.

The company received a favorable UK VAT ruling for Clear Aligners and addressed potential tariff impacts from Mexico and China operations. Looking ahead, Align expects Q2 2025 revenues between $1,050M-$1,070M and projects 2025 revenue growth of 3.5-5.5%, with Clear Aligner volume growth in mid-single digits.